AstraZeneca PLC Signs Cambridge-Based Cancer Research Collaboration

Published: Jul 10, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca Plc (AZN) is pursuing three research projects with the University of Cambridge and Cancer Research UK to try and identify changes in tumor cells and test combinations of its drugs to better treat some cancer patients. The U.K.’s second-biggest drugmaker, which is relocating to Cambridge, England, from London, will work with Cancer Research UK Cambridge Institute and the University of Cambridge Department of Oncology on a new technology that measures tumor DNA circulating in the blood and can identify the presence of cancer in plasma. The test can detect whether cancer is progressing and treatment is working. Doctors now use biopsy or imaging to monitor progression of the disease and whether the patient is responding to treatment.

Help employers find you! Check out all the jobs and post your resume.

Back to news